These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19692124)

  • 21. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
    Wegscheider BJ; Weger M; Renner W; Steinbrugger I; März W; Mossböck G; Temmel W; El-Shabrawi Y; Schmut O; Jahrbacher R; Haas A
    Ophthalmology; 2007 Apr; 114(4):738-42. PubMed ID: 17398321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy.
    Jirarattanasopa P; Ooto S; Nakata I; Tsujikawa A; Yamashiro K; Oishi A; Yoshimura N
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3663-72. PubMed ID: 22570352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Nikkhah H; Bonyadi M; Nazari R; Soheilian M
    Int Ophthalmol; 2019 Apr; 39(4):949-956. PubMed ID: 29423786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pharmacogenomics of CFH Y402H and wet age-related macular degeneration].
    Chen LL; Chen YY
    Zhonghua Yan Ke Za Zhi; 2017 Feb; 53(2):144-147. PubMed ID: 28260367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
    Chaudhary V; Mao A; Hooper PL; Sheidow TG
    Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited macular translocation compared with photodynamic therapy in the management of subfoveal choroidal neovascularization in age-related macular degeneration.
    Pawlak D; Glacet-Bernard A; Papp M; Roquet W; Coscas G; Soubrane G
    Am J Ophthalmol; 2004 May; 137(5):880-7. PubMed ID: 15126153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism.
    Shuler RK; Hauser MA; Caldwell J; Gallins P; Schmidt S; Scott WK; Agarwal A; Haines JL; Pericak-Vance MA; Postel EA
    Arch Ophthalmol; 2007 Jan; 125(1):63-7. PubMed ID: 17210853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study.
    Merle BM; Richard F; Benlian P; Puche N; Delcourt C; Souied EH
    PLoS One; 2015; 10(7):e0130816. PubMed ID: 26132079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement factor H Y402H polymorphism results in diminishing CD4
    Nielsen MK; Subhi Y; Falk M; Singh A; Sørensen TL; Nissen MH; Faber C
    Sci Rep; 2023 Nov; 13(1):19414. PubMed ID: 37940659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
    Ergun E; Maár N; Ansari-Shahrezaei S; Wimpissinger B; Krepler K; Wedrich A; Stur M
    Am J Ophthalmol; 2006 Jul; 142(1):10-16. PubMed ID: 16815246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration.
    Baird PN; Islam FM; Richardson AJ; Cain M; Hunt N; Guymer R
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4194-8. PubMed ID: 17003406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N; Shen Y; Yu CY; Wang SQ; Tong JP
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Joint association of complement component 3 and CC-cytokine ligand2 (CCL2) or complement component 3 and CFH polymorphisms in age-related macular degeneration.
    Bonyadi M; Jabbarpoor Bonyadi MH; Yaseri M; Mohammadian T; Fotouhi N; Javadzadeh A; Soheilian M
    Ophthalmic Genet; 2017; 38(4):365-370. PubMed ID: 28095095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans.
    Kim NR; Kang JH; Kwon OW; Lee SJ; Oh JH; Chin HS
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):2071-6. PubMed ID: 18223247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
    Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.